Related Experiment Video
Updated: Nov 2, 2025

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
Clinical and neuropathological diversity of tauopathy in MAPT duplication carriers
David Wallon1, Susana Boluda2,3, Anne Rovelet-Lecrux4
1Normandie Univ, UNIROUEN, Inserm U1245, CHU Rouen, Department of Neurology and CNR-MAJ, F-76000, Rouen, France. david.wallon@chu-rouen.fr.
Abstract:
Microduplications of the 17q21.31 chromosomal region encompassing the MAPT gene, which encodes the Tau protein, were identified in patients with a progressive disorder initially characterized by severe memory impairment with or without behavioral changes that can clinically mimic Alzheimer disease. The unique neuropathological report showed a primary tauopathy, which could not be unanimously classified in a given known subtype, showing both 4R- and 3R-tau inclusions, mainly within temporal cortical subregions and basal ganglia, without amyloid deposits. Recently, two subjects harboring the same duplication were reported with an atypical extrapyramidal syndrome and gait disorder. To decipher the phenotypic spectrum associated with MAPT duplications, we studied ten carriers from nine families, including two novel unrelated probands, gathering clinical (n = 10), cerebrospinal fluid (n = 6), MRI (n = 8), dopamine transporter scan (n = 4), functional (n = 5), amyloid (n = 3) and Tau-tracer (n = 2) PET imaging data as well as neuropathological examination (n = 4). Ages at onset ranged from 37 to 57 years, with prominent episodic memory impairment in 8/10 patients, associated with behavioral changes in four, while two patients showed atypical extrapyramidal syndrome with gait disorder at presentation, including one with associated cognitive deficits. Amyloid imaging was negative but Tau imaging showed significant deposits mainly in both mesiotemporal cortex. Dopaminergic denervation was found in 4/4 patients, including three without extrapyramidal symptoms. Neuropathological examination exclusively showed Tau-immunoreactive lesions. Distribution, aspect and 4R/3R tau aggregates composition suggested a spectrum from predominantly 3R, mainly cortical deposits well correlating with cognitive and behavioral changes, to predominantly 4R deposits, mainly in the basal ganglia and midbrain, in patients with prominent extrapyramidal syndrome. Finally, we performed in vitro seeding experiments in HEK-biosensor cells. Morphological features of aggregates induced by homogenates of three MAPT duplication carriers showed dense/granular ratios graduating between those induced by homogenates of a Pick disease and a progressive supranuclear palsy cases. These results suggest that MAPT duplication causes a primary tauopathy associated with diverse clinical and neuropathological features.
Insights
Microduplications in the MAPT gene region cause a primary tauopathy, presenting diverse neurological and cognitive symptoms. This condition involves abnormal Tau protein accumulation, mimicking Alzheimer's disease but lacking amyloid plaques.
Area of Science:
- Neuroscience
- Genetics
- Neuropathology
Background:
- Microduplications of the 17q21.31 chromosomal region, including the MAPT gene, are linked to progressive neurological disorders.
- These disorders can mimic Alzheimer's disease with memory impairment and behavioral changes.
- Pathological findings reveal a primary tauopathy with mixed 3R and 4R tau inclusions, distinct from typical Alzheimer's pathology.
Purpose of the Study:
- To delineate the phenotypic spectrum of MAPT duplications.
- To investigate the clinical, imaging, and neuropathological features of MAPT duplication carriers.
- To understand the tau aggregation characteristics in MAPT duplication-associated tauopathy.
Main Methods:
- Clinical assessment of ten MAPT duplication carriers from nine families.
- Cerebrospinal fluid analysis, MRI, dopamine transporter scans, and PET imaging (amyloid and Tau tracers).
- Neuropathological examination of brain tissue and in vitro tau seeding experiments.
Main Results:
- Onset ranged from 37-57 years, with 8/10 patients experiencing memory impairment; two presented with extrapyramidal syndrome and gait issues.
- Amyloid PET was negative; Tau PET showed mesiotemporal cortex deposits. Dopaminergic denervation was observed in all scanned patients.
- Neuropathology confirmed tauopathy with varying 3R/4R tau aggregate ratios, correlating with clinical presentation (cortical for 3R, basal ganglia/midbrain for 4R).
Conclusions:
- MAPT duplication leads to a primary tauopathy with a broad clinical and neuropathological range.
- The tau aggregate composition (3R vs. 4R) influences the clinical phenotype, from cognitive/behavioral to extrapyramidal syndromes.
- In vitro seeding assays reveal tau aggregate characteristics intermediate between Pick's disease and progressive supranuclear palsy.
More Related Videos
09:12Modulation of Tau Subcellular Localization as a Tool to Investigate the Expression of Disease-related Genes
Published on: December 20, 2019
10:38Author Spotlight: Understanding the Impact of Pathological Proteins on Axonal Transport in Neurodegenerative Diseases
Published on: December 22, 2023